

Request for Consultation Breast PDL 1 (SP142)

Audience: External Clients
Issuing Division: Division of Anatomic Pathology
Enquiry: Phone: (416) 480-6100 ext. 4012
E-mail: Karen.Laws@sunnybrook.ca

Dear Colleagues,


We would like to inform you about a new test available at Sunnybrook. PD-L1 testing is available for triple negative breast carcinoma in patients considered for immunotherapy in the setting of locally advanced breast cancer or metastatic breast cancer.

Suitable specimens include FFPE tissue blocks from: breast core biopsy, excision, post neoadjuvant therapy, lymph nodes and distant metastasis. The sample must contain at least 50 invasive tumor cells with intact stroma. The assay cannot be performed on cytology or decalcified material.

Please attach a copy of the report and fill in the designated requisition: [Request for consultation: Breast PD-L1 \(SP142\) testing for triple negative breast carcinoma in patients considered for immunotherapy](https://activenet.sunnybrook.ca/docs/D0150277.docx). The requisition for Consultation for Breast PDL 1 (SP142) can be downloaded using the direct link. This will replace the traditional cover letter. Alternatively you may copy this URL into your browser: <https://activenet.sunnybrook.ca/docs/D0150277.docx>

Should you have any questions regarding this form or about our breast biomarkers consultation service, please do not hesitate to contact us at 416-480-6100, ext.4012 or at any of the numbers below.

Sincerely,



Dr. Sharon Nofech-Mozes
Associate Professor
Sunnybrook Health Sciences Centre
Sharon.nofech-mozes@sunnybrook.ca
Office: (416)480-6100, ext. 3130

Dr. Elzbieta Slodkowska MD FRCPC
Assistant Professor, Breast Pathology Lead
Director of Immunohistochemistry
Sunnybrook Health Sciences Centre
elzbieta.slodkowska@sunnybrook.ca
Office: (416)480-4014